rabivax

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

1.	Ashwathnarayana, D H: 1 article (07/2008)
2.	Bhardwaj, S: 1 article (07/2008)
3.	Bilagumba, Gangaboraiah: 1 article (07/2008)
4.	Mahendra, B J: 1 article (07/2008)
5.	Sanjay, T V: 1 article (07/2008)
6.	Sharma, H: 1 article (07/2008)
7.	Sudarshan, M K: 1 article (07/2008)

1.	Rabies (Hydrophobia) 07/01/2023 - "This was non-interventional active surveillance in patients with category III potential rabies exposure who were administered a post-exposure prophylaxis (PEP) regimen (Rabishield and Rabivax-S) by their healthcare providers (HCPs) as per the dosages and regimens mentioned in the package insert approved by the Indian regulators. " 07/01/2008 - "In conclusion, Rabivax (adsorbed) is an immunogenic, safe and efficacious vaccine for rabies prophylaxis in humans." 07/01/2023 - "A vero cell-based inactivated Rabies Vaccine (Rabivax-S) and Rabies Human Monoclonal Antibody (Rabishield) have been approved since 2016. "
2.	Pain (Aches) 07/01/2008 - "The adverse events to Rabivax (adsorbed) included pain at injection site (3.4%), swelling with induration (2.8%), fever and headache (1.4%). "
3.	Malaria 12/01/2022 - "Eligible children were enrolled and randomly assigned (1:1:1) to receive three vaccinations of either 5 μg R21/25 μg Matrix-M, 5 μg R21/50 μg Matrix-M, or a control vaccine (the Rabivax-S rabies vaccine) before the malaria season, with a booster dose 12 months later. "
4.	Headache (Headaches) 07/01/2008 - "The adverse events to Rabivax (adsorbed) included pain at injection site (3.4%), swelling with induration (2.8%), fever and headache (1.4%). "
5.	Fever (Fevers) 07/01/2008 - "The adverse events to Rabivax (adsorbed) included pain at injection site (3.4%), swelling with induration (2.8%), fever and headache (1.4%). "

1.	Vaccines
2.	Rabies Vaccines (Rabies Vaccine)
3.	Monoclonal Antibodies
4.	Matrix-M